Stock market today: Live updates
Traders work on the floor of the New York Stock Exchange (NYSE) on June 18, 2025 in New…
What’s likely to move the market in the next trading session
Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and…
Novo Nordisk and Omeros announce asset purchase and license
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease…
Stock market today: Live updates
A trader works at the New York Stock Exchange on Oct. 3, 2025. NYSE The S&P 500 and…
Novo Nordisk to acquire Akero Therapeutics and its
Acquisition adds potential first- and best-in-class asset, enhancing Novo Nordisk’s portfolio for treatment of MASH, one of the…
Novo Nordisk to buy Akero Therapeutics
A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of…
Pfizer’s new obesity bet, Metsera, releases drug data
Thomas Fuller | SOPA Images | Lightrocket | Getty Images A version of this article first appeared in…
Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy…
10 things to watch in the stock market Tuesday including Amazon and Oracle
The Club’s 10 things to watch Tuesday, Sept. 16 — Today’s newsletter was written by Jeff Marks, the…
Wegovy-maker Novo Nordisk to cut around 9,000 jobs
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg |…
Novo Nordisk’s Martin Holst Lange previews obesity pill
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news…